19
2020-05
On the last day of 2019, Kintor’s application for a HKEX listing had attracted industry attention. It was reported that with this Hong Kong stock IPO listing on May 22nd 2020 and the global sale of 92
09
2020-05
In 2008, as the first group of pioneers to return to China to conduct research on small molecule anticancer drugs, Dr. Youzhi Tong said, there were not many companies doing new drug research and devel
07
2020-05
Ten years of consistent effort finally bear fruit
In 2008, after nearly 20 years studying and working in the US, Dr. Youzhi Tong made a momentous decision to return to China and start a new drug discovery company. “People who choose to start a busine
16
2020-04
Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement
Suzhou Kintor Pharmaceutical ,Inc. ("Kintor Pharmaceutical ")and Sinopharm Holding Co., Ltd. signed the strategic cooperation agreement on the innovation of topical drug Pyrilutamide (KX-826) in Shanghai. Both sides carry out all-round cooperation on patient-centered product design, future business channel development and terminal services, so as to prepare for future market development and better service for patients.
28
2020-02
To further strengthen the support and speed up the cultivation of a group of leading biopharmaceutical enterprises with global influence, the Party Working Committee and Management Committee of the park carried out a comprehensive and detailed sorting of biopharmaceutical enterprises in the park and selected a group of leading enterprises with independent brands.
17
2020-02
Suzhou Kintor Obtained Approval to Conduct Clinical Trials for SMO Antagonists in China
On February 17, 2020, National Medical Products Administration officially granted the clinical trials notification to Suzhou Kintor Pharmaceuticals, Inc.(hereinafter referred to as “Suzhou Kintor") and agreed to approve clinical trials to be conducted on the SMO antagonist, GT1708F.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn